$1.74 Earnings Per Share Expected for West Pharmaceutical Services, Inc. (NYSE:WST) This Quarter

Equities analysts expect West Pharmaceutical Services, Inc. (NYSE:WST) to report earnings of $1.74 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for West Pharmaceutical Services’ earnings, with the highest EPS estimate coming in at $1.85 and the lowest estimate coming in at $1.68. West Pharmaceutical Services reported earnings of $1.25 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 39.2%. The firm is scheduled to issue its next earnings results before the market opens on Thursday, July 29th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full year earnings of $7.16 per share for the current year, with EPS estimates ranging from $7.07 to $7.40. For the next fiscal year, analysts anticipate that the business will post earnings of $7.75 per share, with EPS estimates ranging from $7.35 to $8.00. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 29th. The medical instruments supplier reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.63. West Pharmaceutical Services had a net margin of 18.19% and a return on equity of 25.08%. The company had revenue of $670.70 million during the quarter, compared to analysts’ expectations of $614.77 million.

Separately, Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $355.00 target price on the stock in a research report on Wednesday, April 21st.

Shares of NYSE WST traded up $6.02 during trading on Thursday, hitting $373.97. The company had a trading volume of 8,588 shares, compared to its average volume of 340,820. The firm’s fifty day simple moving average is $351.83. West Pharmaceutical Services has a fifty-two week low of $252.80 and a fifty-two week high of $377.19. The firm has a market capitalization of $27.61 billion, a price-to-earnings ratio of 64.37, a price-to-earnings-growth ratio of 2.02 and a beta of 0.99. The company has a quick ratio of 2.11, a current ratio of 2.75 and a debt-to-equity ratio of 0.14.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 4th. Investors of record on Wednesday, July 21st will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 20th. This represents a $0.68 dividend on an annualized basis and a yield of 0.18%. West Pharmaceutical Services’s payout ratio is presently 14.29%.

In related news, insider Silji Abraham sold 2,171 shares of the business’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $335.00, for a total transaction of $727,285.00. Following the transaction, the insider now directly owns 6,077 shares in the company, valued at $2,035,795. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.66% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of WST. FMR LLC boosted its position in West Pharmaceutical Services by 41.3% during the first quarter. FMR LLC now owns 794 shares of the medical instruments supplier’s stock worth $88,000 after acquiring an additional 232 shares during the last quarter. Renaissance Technologies LLC acquired a new position in West Pharmaceutical Services in the 4th quarter valued at about $12,522,000. Veriti Management LLC acquired a new position in West Pharmaceutical Services in the 4th quarter valued at about $33,000. Baird Financial Group Inc. acquired a new position in West Pharmaceutical Services in the 4th quarter valued at about $377,000. Finally, Eqis Capital Management Inc. acquired a new position in West Pharmaceutical Services in the 4th quarter valued at about $210,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.

Recommended Story: LIBOR

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.